Login / Signup

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.

Valentina Cordo'Jordy C G van der ZwetKirsten Canté-BarrettRob PietersJules P P Meijerink
Published in: Blood cancer discovery (2020)
T-ALL is driven by oncogenic transcription factors that act along with secondary acquired mutations. These lesions, together with active signaling pathways, may be targeted by therapeutic agents. Bridging research and clinical practice can accelerate the testing of novel treatments in clinical trials, offering an opportunity for patients with poor outcome.
Keyphrases